Decreased Cerebral α4β2* Nicotinic Acetylcholine Receptor Availability in Patients with Mild Cognitive Impairment and Alzheimer's Disease Assessed with Positron Emission Tomography

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2010 Nov 12

PMID 21069319

Citations 52

Authors

Kai Kendziorra

Henrike Wolf

Philipp Mael Meyer

Henryk Barthel

Swen Hesse

Georg Alexander Becker

Julia Luthardt

Andreas Schildan

Marianne Patt

Dietlind Sorger

Anita Seese

Herman-Josef Gertz

Osama Sabri

Affiliations

Soon will be listed here.

Abstract

Purpose: Postmortem studies indicate a loss of nicotinic acetylcholine receptor (nAChRs) in Alzheimer's disease (AD). In order to establish whether these changes in the cholinergic system occur at an early stage of AD, we carried out positron emission tomography (PET) with a specific radioligand for the α4β2* nicotinic acetylcholine receptor (α4β2* nAChR) in patients with mild to moderate AD and in patients with amnestic mild cognitive impairment (MCI), who have a high risk to progress to AD.

Methods: Nine patients with moderate AD, eight patients with MCI and seven age-matched healthy controls underwent 2-[(18)F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[(18)F]FA-85380) PET. After coregistration with individual magnetic resonance imaging the binding potential (BP(ND)) of 2-[(18)F]FA-85380 was calculated using either the corpus callosum or the cerebellum as reference regions. PET data were analysed by region of interest analysis and by voxel-based analysis.

Results: Both patients with AD and MCI showed a significant reduction in 2-[(18)F]FA-85380 BP(ND) in typical AD-affected brain regions. Thereby, the corpus callosum was identified as the most suitable reference region. The 2-[(18)F]FA-85380 BP(ND) correlated with the severity of cognitive impairment. Only MCI patients that converted to AD in the later course (n = 5) had a reduction in 2-[(18)F]FA-85380 BP(ND).

Conclusion: 2-[(18)F]FA-85380 PET appears to be a sensitive and feasible tool for the detection of a reduction in α4β2* nAChRs which seems to be an early event in AD. In addition, 2-[(18)F]FA-85380 PET might give prognostic information about a conversion from MCI to AD.

Citing Articles

Alterations in Neuronal Nicotinic Acetylcholine Receptors in the Pathogenesis of Various Cognitive Impairments.

Guan Z CNS Neurosci Ther. 2024; 30(10):e70069.

PMID: 39370620 PMC: 11456617. DOI: 10.1111/cns.70069.

TMS-derived short afferent inhibition discriminates cognitive status in older adults without dementia.

Sundman M, Green J, Fuglevand A, Chou Y Aging Brain. 2024; 6:100123.

PMID: 39132326 PMC: 11315225. DOI: 10.1016/j.nbas.2024.100123.

Xanomeline restores endogenous nicotinic acetylcholine receptor signaling in mouse prefrontal cortex.

Power S, Venkatesan S, Lambe E Neuropsychopharmacology. 2023; 48(4):671-682.

PMID: 36635596 PMC: 9938126. DOI: 10.1038/s41386-023-01531-5.

Characterization of Altered Molecular Pathways in the Entorhinal Cortex of Alzheimer's Disease Patients and In Silico Prediction of Potential Repurposable Drugs.

Fagone P, Mangano K, Martino G, Quattropani M, Pennisi M, Bella R Genes (Basel). 2022; 13(4).

PMID: 35456509 PMC: 9028005. DOI: 10.3390/genes13040703.

Cholinergic receptor binding in unimpaired older adults, mild cognitive impairment, and Alzheimer's disease dementia.

Sultzer D, Lim A, Gordon H, Yarns B, Melrose R Alzheimers Res Ther. 2022; 14(1):25.

PMID: 35130968 PMC: 8819935. DOI: 10.1186/s13195-021-00954-w.

References

Rinne J, Myllykyla T, Lonnberg P, Marjamaki P . A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res. 1991; 547(1):167-70. DOI: 10.1016/0006-8993(91)90588-m. View

Bowen D, Benton J, Spillane J, Smith C, Allen S . Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients. J Neurol Sci. 1982; 57(2-3):191-202. DOI: 10.1016/0022-510x(82)90026-0. View

Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N . Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002; 15(1):273-89. DOI: 10.1006/nimg.2001.0978. View

Gallezot J, Bottlaender M, Delforge J, Valette H, Saba W, Dolle F . Quantification of cerebral nicotinic acetylcholine receptors by PET using 2-[18F]fluoro-A-85380 and the multiinjection approach. J Cereb Blood Flow Metab. 2007; 28(1):172-89. DOI: 10.1038/sj.jcbfm.9600505. View

OBrien J, Colloby S, Pakrasi S, Perry E, Pimlott S, Wyper D . Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography. J Neurol Neurosurg Psychiatry. 2006; 78(4):356-62. PMC: 2077777. DOI: 10.1136/jnnp.2006.108209. View

Bartus R, Dean 3rd R, Beer B, Lippa A . The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982; 217(4558):408-14. DOI: 10.1126/science.7046051. View

Davis K, Mohs R, Marin D, Purohit D, Perl D, Lantz M . Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999; 281(15):1401-6. DOI: 10.1001/jama.281.15.1401. View

Schildan A, Patt M, Sabri O . Synthesis procedure for routine production of 2-[18F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[18F]F-A-85380). Appl Radiat Isot. 2007; 65(11):1244-8. DOI: 10.1016/j.apradiso.2007.02.009. View

Pimlott S, Piggott M, Owens J, Greally E, Court J, Jaros E . Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology. 2003; 29(1):108-16. DOI: 10.1038/sj.npp.1300302. View

10.

Martin-Ruiz C, Court J, Molnar E, Lee M, Gotti C, Mamalaki A . Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J Neurochem. 1999; 73(4):1635-40. DOI: 10.1046/j.1471-4159.1999.0731635.x. View

11.

Arendt T, Bigl V . Alzheimer's disease as a presumptive threshold phenomenon. Neurobiol Aging. 1987; 8(6):552-4. DOI: 10.1016/0197-4580(87)90131-x. View

12.

Mitsis E, Reech K, Bois F, Tamagnan G, MacAvoy M, Seibyl J . 123I-5-IA-85380 SPECT imaging of nicotinic receptors in Alzheimer disease and mild cognitive impairment. J Nucl Med. 2009; 50(9):1455-63. DOI: 10.2967/jnumed.109.064030. View

13.

Terriere E, Dempsey M, Herrmann L, Tierney K, Lonie J, OCarroll R . 5-(123)I-A-85380 binding to the α4β2-nicotinic receptor in mild cognitive impairment. Neurobiol Aging. 2008; 31(11):1885-93. DOI: 10.1016/j.neurobiolaging.2008.10.008. View

14.

Chefer S, London E, Koren A, Pavlova O, Kurian V, Kimes A . Graphical analysis of 2-[18F]FA binding to nicotinic acetylcholine receptors in rhesus monkey brain. Synapse. 2003; 48(1):25-34. DOI: 10.1002/syn.10180. View

15.

Ellis J, Villemagne V, Nathan P, Mulligan R, Gong S, Chan J . Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study. Neurobiol Learn Mem. 2008; 90(2):404-12. DOI: 10.1016/j.nlm.2008.05.006. View

16.

Giovacchini G, Conant S, Herscovitch P, Theodore W . Using cerebral white matter for estimation of nondisplaceable binding of 5-HT1A receptors in temporal lobe epilepsy. J Nucl Med. 2009; 50(11):1794-800. PMC: 3059591. DOI: 10.2967/jnumed.109.063743. View

17.

Soonawala D, Amin T, Ebmeier K, Douglas Steele J, Dougall N, Best J . Statistical parametric mapping of (99m)Tc-HMPAO-SPECT images for the diagnosis of Alzheimer's disease: normalizing to cerebellar tracer uptake. Neuroimage. 2002; 17(3):1193-202. DOI: 10.1006/nimg.2002.1259. View

18.

Sorger D, Becker G, Hauber K, Schildan A, Patt M, Birkenmeier G . Binding properties of the cerebral alpha4beta2 nicotinic acetylcholine receptor ligand 2-[18F]fluoro-A-85380 to plasma proteins. Nucl Med Biol. 2006; 33(7):899-906. DOI: 10.1016/j.nucmedbio.2006.07.012. View

19.

Terriere E, Sharman M, Donaghey C, Herrmann L, Lonie J, Strachan M . alpha4beta2-nicotinic receptor binding with 5-IA in Alzheimer's disease: methods of scan analysis. Neurochem Res. 2007; 33(4):643-51. DOI: 10.1007/s11064-007-9517-4. View

20.

Nordberg A, Lundqvist H, Hartvig P, Lilja A, Langstrom B . Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains--in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord. 1995; 9(1):21-7. DOI: 10.1097/00002093-199505000-00006. View